The clinical trial ecosystem is entering a phase of consolidation and reinvention driven by the collapse of boundaries between functions, data, and even companies themselves.

In 2026, clinical trial teams market uncertainty and identify high-impact areas for AI adoption to remain competitive.

Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. In addition to potentially saving the healthcare industry upwards of $360 billion annually, ...

Delivering FDB's knowledge and capabilities through MCP advances company's market leadership in drug knowledge innovation, introducing new ways for AI agents and large language models to leverage ...

Venezia Chosen to Lead the Growth of the Innovative Research Protocol Automation Platform NEW YORK CITY, Aug. 23, 2022 /PRNewswire/ -- ProofPilot, the protocol automation platform for clinical trials, ...

The collaboration will enable researchers to remotely access consenting participants' electronic health data, improving the cost and quality of patient monitoring NEW YORK, Aug. 31, 2022 /PRNewswire/ ...

Laboratory automation typically involves integrating key instrumentation with liquid- and microplate-handling robots creating workcells that are often designed for a single protocol. The scheduling ...

As the curtain closed on 2024, FDA issued a new draft guidance to assist clinical trial sponsors, investigators, and institutional review boards (“IRBs”) with defining, identifying, and reporting ...

Artificial Intelligence (AI) is transforming industrial automation with robotics, smart factory equipment and programmable systems. However, the cost efficiencies and performance gains AI delivers are ...

The Model Context Protocol (MCP) is poised to redefine how artificial intelligence (AI) agents interact with external tools and services. Imagine a world where connecting AI systems to external AI ...